Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge.
作者信息
Baden Lindsey R, El Sahly Hana M, Essink Brandon, Follmann Dean, Neuzil Kathleen M, August Allison, Clouting Heather, Fortier Gabrielle, Deng Weiping, Han Shu, Zhao Xiaoping, Leav Brett, Talarico Carla, Girard Bethany, Paila Yamuna D, Tomassini Joanne E, Schödel Florian, Pajon Rolando, Zhou Honghong, Das Rituparna, Miller Jacqueline
机构信息
Brigham and Women's Hospital, Boston, MA
Baylor College of Medicine, Houston, TX
出版信息
N Engl J Med. 2021 Dec 23;385(26):2485-2487. doi: 10.1056/NEJMc2115597. Epub 2021 Nov 3.
Abstract
摘要
相似文献
1
Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge.
N Engl J Med. 2021 Dec 23;385(26):2485-2487. doi: 10.1056/NEJMc2115597. Epub 2021 Nov 3.
2
Covid-19 in the Phase 3 Trial of mRNA-1273 During the Delta-variant Surge.
medRxiv. 2021 Sep 22:2021.09.17.21263624. doi: 10.1101/2021.09.17.21263624.
3
COVID-19 Vaccine Initiation and Dose Completion During the SARS-CoV-2 Delta Variant Surge in the United States, December 2020-October 2021.
Public Health Rep. 2023 Jan-Feb;138(1):183-189. doi: 10.1177/00333549221123584. Epub 2022 Sep 21.
4
Levels of messenger ribonucleic acid for cholesterol side-chain cleavage cytochrome P-450 and 3 beta-hydroxysteroid dehydrogenase in bovine preovulatory follicles decrease after the luteinizing hormone surge.
Endocrinology. 1993 Feb;132(2):888-94. doi: 10.1210/endo.132.2.8425501.
5
Real-world vaccine effectiveness of mRNA vaccines for SARS-CoV-2; a test-negative case-control study in a medium-sized clinic.
Hum Vaccin Immunother. 2022 Dec 30;18(7):2147353. doi: 10.1080/21645515.2022.2147353. Epub 2022 Dec 2.
6
SARS-CoV-2 B.1.1.529 (Omicron) Variant Causes an Unprecedented Surge in Children Hospitalizations and Distinct Clinical Presentation Compared to the SARS-CoV-2 B.1.617.2 (Delta) Variant.
Front Pediatr. 2022 Jun 27;10:932170. doi: 10.3389/fped.2022.932170. eCollection 2022.
7
Levels of messenger ribonucleic acid for cytochrome P450 17 alpha-hydroxylase and P450 aromatase in preovulatory bovine follicles decrease after the luteinizing hormone surge.
Endocrinology. 1993 May;132(5):2239-45. doi: 10.1210/endo.132.5.8477668.
8
Measuring the Effectiveness of COVID-19 Vaccines Used during a Surge of the Delta Variant of SARS-CoV-2 in Bangladesh: A Test-Negative Design Evaluation.
Vaccines (Basel). 2022 Dec 2;10(12):2069. doi: 10.3390/vaccines10122069.
9
Oxytocin/neurophysin-I messenger ribonucleic acid in bovine granulosa cells increases after the luteinizing hormone (LH) surge and is stimulated by LH in vitro.
Endocrinology. 1992 Dec;131(6):2755-62. doi: 10.1210/endo.131.6.1446614.
10
COVID-19 chest CT and laboratory features of B.1.617.2 (Delta variant) vs B.1.1.7 (Alpha variant) surge: a single center case-control study.
Infez Med. 2022 Dec 1;30(4):555-562. doi: 10.53854/liim-3004-10. eCollection 2022.
引用本文的文献
1
Highly immunogenic DNA/LION nanocarrier vaccine potently activates lymph nodes inducing long-lasting immunity in macaques.
iScience. 2025 Mar 18;28(4):112232. doi: 10.1016/j.isci.2025.112232. eCollection 2025 Apr 18.
2
Use of 3M-052-AF with Alum adjuvant in HIV trimer vaccine induces human autologous neutralizing antibodies.
J Exp Med. 2024 Oct 7;221(10). doi: 10.1084/jem.20240604. Epub 2024 Sep 5.
3
Mucosal adenovirus vaccine boosting elicits IgA and durably prevents XBB.1.16 infection in nonhuman primates.
Nat Immunol. 2024 Oct;25(10):1913-1927. doi: 10.1038/s41590-024-01951-5. Epub 2024 Sep 3.
4
Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases.
Nat Commun. 2024 Aug 29;15(1):7469. doi: 10.1038/s41467-024-50376-z.
5
Long-Term Safety and Immunogenicity of AZD1222 (ChAdOx1 nCoV-19): 2-Year Follow-Up from a Phase 3 Study.
Vaccines (Basel). 2024 Aug 3;12(8):883. doi: 10.3390/vaccines12080883.
6
Durability of Protection Against COVID-19 Through the Delta Surge for the NVX-CoV2373 Vaccine.
Clin Infect Dis. 2024 Jul 19;79(1):78-85. doi: 10.1093/cid/ciae081.
7
Extraordinary Titer and Broad Anti-SARS-CoV-2 Neutralization Induced by Stabilized RBD Nanoparticles from Strain BA.5.
Vaccines (Basel). 2023 Dec 28;12(1):37. doi: 10.3390/vaccines12010037.
8
Efficacy of Messenger RNA-1273 Against Severe Acute Respiratory Syndrome Coronavirus 2 Acquisition in Young Adults From March to December 2021.
Open Forum Infect Dis. 2023 Nov 2;10(11):ofad511. doi: 10.1093/ofid/ofad511. eCollection 2023 Nov.
9
Delineation of DNA and mRNA COVID-19 vaccine-induced immune responses in preclinical animal models.
Hum Vaccin Immunother. 2023 Dec 15;19(3):2281733. doi: 10.1080/21645515.2023.2281733. Epub 2023 Nov 27.
10
The effects of combination-therapy of tocilizumab and baricitinib on the management of severe COVID-19 cases: a randomized open-label clinical trial.
Front Pharmacol. 2023 Oct 19;14:1265541. doi: 10.3389/fphar.2023.1265541. eCollection 2023.
本文引用的文献
1
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase.
N Engl J Med. 2021 Nov 4;385(19):1774-1785. doi: 10.1056/NEJMoa2113017. Epub 2021 Sep 22.
2
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant.
N Engl J Med. 2021 Aug 12;385(7):585-594. doi: 10.1056/NEJMoa2108891. Epub 2021 Jul 21.
3
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.
Zotero 插件